Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM in Patients With Septic Shock. A Randomised, Double-blind, Two-Stage, Placebo Controlled Study
Phase of Trial: Phase II
Latest Information Update: 30 Jan 2019
At a glance
- Drugs Nangibotide (Primary)
- Indications Septic shock
- Focus Adverse reactions
- Sponsors Inotrem
- 30 Sep 2018 Results presented in an Inotrem media release.
- 30 Sep 2018 According to an Inotrem media release, data from this study were presented at the annual congress of the International Sepsis Forum.
- 31 Aug 2018 Biomarkers information updated